GLUL as a novel therapeutic target in pediatric T-ALL
GLUL as a novel therapeutic target in pediatric T-ALL
Dr. Daniel Herranz, Ph.D. – Rutgers Biomedical and Health Sciences (Rutgers Health), New Brunswick, NJ
Linking the Gut Microbiome to Chemotherapy Toxicity in Pediatric ALL
Linking the Gut Microbiome to Chemotherapy Toxicity in Pediatric ALL
Dr. Eran Elinav, M.D., Ph.D. – Weizmann Institute of Science, Israel
Deciphering mutually exclusive T-ALL and neurodevelopmental mutations in the ARD domain of the ZMIZ1 coactivator
Deciphering mutually exclusive T-ALL and neurodevelopmental mutations in the ARD domain of the ZMIZ1 coactivator
Dr. Mark Chiang, M.D., Ph.D. – The Regents of the University of Michigan, Ann Arbor, MI
Cooperative mutagenesis driving pediatric pre-B cell leukemia
Cooperative mutagenesis driving pediatric pre-B cell leukemia
Dr. Abby Green, M.D. – Washington University, School of Medicine, St. Louis, MO
Dietary valine modulation to enhance therapies for high-risk T-ALL
Dietary valine modulation to enhance therapies for high-risk T-ALL
Dr. Palaniraja Thandapani, Ph.D. – University of Texas M.D. Anderson Cancer Center, Houston, TX
Validating PRL2 as a New Therapeutic Target in T-ALL
Validating PRL2 as a New Therapeutic Target in T-ALL
Dr. Loretta Li, M.D. – Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
The Role of S100A8/A9-IL6R in B-ALL Chemoresistance
The Role of S100A8/A9-IL6R in B-ALL Chemoresistance
Dr. William Carroll, M.D. – New York University Grossman School of Medicine, New York, NY
Modeling relapsed hypodiploid B-cell acute lymphoblastic leukemia using humanized in vivo systems
Modeling relapsed hypodiploid B-cell acute lymphoblastic leukemia using humanized in vivo systems
Dr. Matthew Witkowski – University of Colorado Denver, AMC and DC
Role of PAX5 mutations in B-cell acute lymphoblastic leukemia
Role of PAX5 mutations in B-cell acute lymphoblastic leukemia
Dr. Zhaohui Gu – Beckman Research Institute of the City of Hope, Duarte, CA
Activating type I interferon-driven immune surveillance to treat pediatric B-cell acute lymphoblastic leukemia
Activating type I interferon-driven immune surveillance to treat pediatric B-cell acute lymphoblastic leukemia
Beckman Research Institute of the City of Hope, Duarte, CA
Targeting the IKAROS-SAMHD1 axis in KMT2A rearranged B-ALL
Targeting the IKAROS-SAMHD1 axis in KMT2A rearranged B-ALL
Baylor College of Medicine, Houston, TX
Pediatric ALL CAR T-Cell Therapy
Pediatric ALL CAR T-Cell Therapy
Seattle Children’s Hospital, Seattle, WA